We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Integrated Database Helps Detect Biomarkers to Neurological Diseases

By LabMedica International staff writers
Posted on 20 May 2009
A searchable, integrated database of human genes provides concise genomic, proteomic, transcriptomic, genetic, and functional information on all known and predicted human genes. More...
It will be used to identify and characterize protein biomarkers for serious neurological diseases.

Information featured in the database, which is called GeneCards, includes orthologies, disease relationships, mutations and single nucleotide polymorphisms (SNPs), gene expression, gene function, pathways, protein-protein interactions, related drugs and compounds, and direct links to research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents.

GeneCards was developed by a bioinformatics team at the Weizmann Institute of Science (Rehovot, Israel) directed by Marilyn Safran and Prof. Doron Lancet of the department of molecular genetics, and head of the Crown Human Genome Center.

Xennex (Cambridge MA, USA) has provided Satoris (Redwood City, CA, USA) with access to GeneCards and associated tools. Satoris is utilizing GeneCards and the related technology for investigations related to its identification and characterization of protein biomarkers associated with neurological disease such as Alzheimer's, Parkinson's, multiple sclerosis, and diabetic neuropathy, to create new diagnostic tools for earlier, better healthcare decisions.

The newly released GeneCards Version 3.0 features a significantly upgraded infrastructure, including a comprehensive relational biological database, and a sophisticated, and speedier search engine. It provides capabilities for effective and well-targeted queries, a user-friendly display, and clear data navigation. Also released, a preliminary version of GeneDecks Version 3, which makes use of the new GeneCards relational database for complex analyses on sets of genes.

Dr. David Warshawsky, president & CEO of Xennex, stated: "We are very pleased that we can offer Satoris our most advanced tools and the latest GeneCards developments to assist in their work. Satoris' work is of great potential for improved diagnosis and treatment of devastating conditions."

Related Links:

GeneCards
Weizmann Institute of Science
Xennex
Satoris



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.